1. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study;Kirsebom;Lancet Infect Dis,2023
2. Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation in England;Kirsebom FCM;EClinicalMedicine,2024
3. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023
4. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults—VISION network, nine states, September-November 2022;Tenforde;MMWR Morbidity Mortality Wkly Rep,2022
5. UK Health Security Agency. National Influenza and COVID-19 surveillance report: Week 9 report (up to week 8 data) 2024 [Available from: https://assets.publishing.service.gov.uk/media/65e07c292f2b3b001c7cd778/Weekly-flu-and-COVID-19-surveillance-report-week-9.pdf.